OncoSec Shares Slump Premarket as Keytruda Combo Study Fails

Dow Jones

Apr 03, 2023

By Colin Kellaher

Shares of OncoSec Medical Inc. dropped more than 60% in premarket trading Monday after the clinical-stage biotechnology company reported the failure of its lead drug candidate in a Phase 2 combination study with Merck & Co.'s blockbuster cancer drug Keytruda.

The Pennington, N.J., company said the single-arm trial evaluating TAVO-EP in combination with Keytruda in patients with unresectable or metastatic melanoma missed the primary endpoint of overall response rate.

OncoSec said it now plans to pursue TAVO-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting.

OncoSec shares, which closed Friday at $2.58, were recently down 61% to $1 in premarket trading. The stock has gained about 53% in the first three months of 2023.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 03, 2023 07:22 ET (11:22 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2324669828"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2324669828\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2324669828?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-03 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2324669828","market":"us","top_or_hot":-1,"title":"OncoSec Shares Slump Premarket as Keytruda Combo Study Fails","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of OncoSec Medical Inc. dropped more than 60% in premarket trading Monday after the clinical-stage biotechnology company reported the failure of its lead drug candidate in a Phase 2 combination study with Merck &amp; Co.'s blockbuster cancer drug Keytruda. \n</p>\n<p>\n  The Pennington, N.J., company said the single-arm trial evaluating TAVO-EP in combination with Keytruda in patients with unresectable or metastatic melanoma missed the primary endpoint of overall response rate. \n</p>\n<p>\n  OncoSec said it now plans to pursue TAVO-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting. \n</p>\n<p>\n  OncoSec shares, which closed Friday at $2.58, were recently down 61% to $1 in premarket trading. The stock has gained about 53% in the first three months of 2023. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2023 07:22 ET (11:22 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OncoSec Shares Slump Premarket as Keytruda Combo Study Fails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncoSec Shares Slump Premarket as Keytruda Combo Study Fails\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-04-03 19:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of OncoSec Medical Inc. dropped more than 60% in premarket trading Monday after the clinical-stage biotechnology company reported the failure of its lead drug candidate in a Phase 2 combination study with Merck &amp; Co.'s blockbuster cancer drug Keytruda. \n</p>\n<p>\n  The Pennington, N.J., company said the single-arm trial evaluating TAVO-EP in combination with Keytruda in patients with unresectable or metastatic melanoma missed the primary endpoint of overall response rate. \n</p>\n<p>\n  OncoSec said it now plans to pursue TAVO-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting. \n</p>\n<p>\n  OncoSec shares, which closed Friday at $2.58, were recently down 61% to $1 in premarket trading. The stock has gained about 53% in the first three months of 2023. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2023 07:22 ET (11:22 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014575.USD","symbol_name":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2324669828","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2324669828","pubTimestamp":1680520920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"By Colin Kellaher \n\n\n \n\n\n  Shares of OncoSec Medical Inc. dropped more than 60% in premarket trading","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","SG9999002232.USD":"Allianz Global High Payout USD","TERN":"Terns Pharmaceuticals, Inc.","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","MRK":"默沙东","BK4534":"瑞士信贷持仓","BK4139":"生物科技","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0861579265.USD":"联博低波幅策略股票基金A","CRCT":"Cricut, Inc.","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","BK4516":"特朗普概念","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK4559":"巴菲特持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4191":"家用电器","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999001176.USD":"United Global Healthcare Acc USD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4550":"红杉资本持仓","BK4588":"碎股","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK4007":"制药"},"translate_title":"Keytruda组合研究失败，OncoSec股价盘前暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1,"TERN":0.72,"ONCS":0.9,"CRCT":0.72},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Shares of OncoSec Medical Inc. dropped more than 60% in premarket trading Monday after the clinical-stage biotechnology company reported the failure of its lead drug candidate in a Phase 2 combination study with Merck & Co.'s blockbuster cancer drug Keytruda. \n\n\n  The Pennington, N.J., company said the single-arm trial evaluating TAVO-EP in combination with Keytruda in patients with unresectable or metastatic melanoma missed the primary endpoint of overall response rate. \n\n\n  OncoSec said it now plans to pursue TAVO-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting. \n\n\n  OncoSec shares, which closed Friday at $2.58, were recently down 61% to $1 in premarket trading. The stock has gained about 53% in the first three months of 2023. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2023 07:22 ET (11:22 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}